metformin + atorvastatin (Tanta University)

This refers to a clinical investigation (Phase 4, NCT05507398) conducted by Tanta University evaluating the repurposed use of metformin and atorvastatin as adjuvant therapies in patients with stage I-III non-metastatic breast cancer. Metformin, a biguanide typically used for type 2 diabetes, acts as an AMPK activator and may inhibit cancer cell proliferation by reducing insulin levels and activating the LKB1/AMPK pathway. Atorvastatin, an HMG-CoA reductase inhibitor used for hyperlipidemia, targets the mevalonate pathway, potentially inhibiting protein prenylation and cholesterol synthesis necessary for tumor growth. The study compares the anti-tumor efficacy of these two agents when added to standard chemotherapy in a comparative clinical setting.

Other names

metformin and atorvastatin